Antidote's story was recently featured in the Clinical Leader, with comments from a top partner, JDRF.
"Getting new treatments to patients is a long and costly endeavor. Most drugs take upward of eight years and billions of dollars to receive regulatory approval. One of the biggest problems sponsor companies face when trying to launch a Phase 3 trial is finding enough patients to take part in the study."
Read more at ClinicalLeader.com.